Abstract
This paper describes the synthesis and in vitro biological activities of imidazolidine and hexahydropyrimidine derivatives against bacteria (Escherichia coli, Staphylococcus aureus and Mycobacterium tuberculosis) and Leishmania protozoa. Out of sixteen heterocyclic derivatives tested, none were cytotoxic against mammalian cells. The compounds showed significant bacterial effects and leishmanicidal activity. Compounds 4a and 4c were active against S. aureus and E. coli, respectively. Compounds 3a-3f, 4h and 4i presented promising results against M. tuberculosis, with MIC values ranging from 12.5 to 25.0 μg/mL, comparable to the “first and second line” drugs used to treat tuberculosis. Compounds 4a, 4c and 4e were active against L major. Three of them were structurally characterized by single-crystal X-ray diffraction.
Keywords: Synthesis, Cytotoxicity, Antibacterial, Antileishmanial, Biological Activities, Imidazolidine, Hexahydropyrimidine Derivatives, X-ray crystallography, Mycobacterium tuberculosis, heterocyclic compounds, E. coli
Medicinal Chemistry
Title:Synthesis, Cytotoxicity, Antibacterial and Antileishmanial Activities of Imidazolidine and Hexahydropyrimidine Derivatives
Volume: 9 Issue: 3
Author(s): Gustavo S. G. de Carvalho, Rafael M. P. Dias, Fernando R. Pavan, Clarice Q. F. Leite, Vania L. Silva, Claudio G. Diniz, Daniela T. S. de Paula, Elaine S. Coimbra, Pascal Retailleau and Adilson D. da Silva
Affiliation:
Keywords: Synthesis, Cytotoxicity, Antibacterial, Antileishmanial, Biological Activities, Imidazolidine, Hexahydropyrimidine Derivatives, X-ray crystallography, Mycobacterium tuberculosis, heterocyclic compounds, E. coli
Abstract: This paper describes the synthesis and in vitro biological activities of imidazolidine and hexahydropyrimidine derivatives against bacteria (Escherichia coli, Staphylococcus aureus and Mycobacterium tuberculosis) and Leishmania protozoa. Out of sixteen heterocyclic derivatives tested, none were cytotoxic against mammalian cells. The compounds showed significant bacterial effects and leishmanicidal activity. Compounds 4a and 4c were active against S. aureus and E. coli, respectively. Compounds 3a-3f, 4h and 4i presented promising results against M. tuberculosis, with MIC values ranging from 12.5 to 25.0 μg/mL, comparable to the “first and second line” drugs used to treat tuberculosis. Compounds 4a, 4c and 4e were active against L major. Three of them were structurally characterized by single-crystal X-ray diffraction.
Export Options
About this article
Cite this article as:
S. G. de Carvalho Gustavo, M. P. Dias Rafael, R. Pavan Fernando, Q. F. Leite Clarice, L. Silva Vania, G. Diniz Claudio, T. S. de Paula Daniela, S. Coimbra Elaine, Retailleau Pascal and D. da Silva Adilson, Synthesis, Cytotoxicity, Antibacterial and Antileishmanial Activities of Imidazolidine and Hexahydropyrimidine Derivatives, Medicinal Chemistry 2013; 9 (3) . https://dx.doi.org/10.2174/1573406411309030005
DOI https://dx.doi.org/10.2174/1573406411309030005 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index To Volume 8
Protein & Peptide Letters Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Internet Resources for Drug Discovery and Design
Current Topics in Medicinal Chemistry Vanadium Complexes with Hydrazone or Thiosemicarbazone Ligands as Potential Anti-Mycobacterium tuberculosis Agents
Current Clinical Pharmacology Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 1: General Overview with a Focus on Ascorbic Acid
Inflammation & Allergy - Drug Targets (Discontinued) Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening NAD(P) Biosynthesis Enzymes as Potential Targets for Selective Drug Design
Current Medicinal Chemistry Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies
Current Medicinal Chemistry New Pyrroles with Potential Antimycobacterial, Antifungal and Selective COX-2 Inhibiting Activities. Synthetic Methodologies
Current Organic Chemistry Design, Synthesis and Evaluation of Thiourea Derivatives as Antimicrobial and Antiviral Agents
Letters in Drug Design & Discovery Artificial Neural Network Analysis of Pharmacokinetic and Toxicity Properties of Lead Molecules for Dengue Fever, Tuberculosis and Malaria
Current Computer-Aided Drug Design Bicyclic 6 + 6 Systems: Advances in the Chemistry of Heterocyclic Compounds Incorporated Pyrimido[1,2-a]Pyrimidine Skeleton
Mini-Reviews in Organic Chemistry Transcriptional Regulation and Expression of CYP3A4 in Hepatocytes
Current Drug Metabolism Privileged Structures in the Design of Potential Drug Candidates for Neglected Diseases
Current Medicinal Chemistry Non-Clinical Investigation of Tuberculosis Drugs: Conjugated Norbornene- Based Nanocarriers Toxic Impacts on Zebrafish
Current Nanomedicine Antibiotic Sensitivity of Bacillus clausii Strains in Commercial Preparation
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Computational Enzymology and Organophosphorus Degrading Enzymes: Promising Approaches Toward Remediation Technologies of Warfare Agents and Pesticides
Current Medicinal Chemistry The Role of IL-15 Signaling in the Induction of Innate Antiviral Responses
Current Signal Transduction Therapy Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Prevalence of Tuberculosis in a Prison in Tehran by Active Case Finding
Infectious Disorders - Drug Targets